Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Annamycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Moleculin Hits 45-Patient Enrollment Milestone in MIRACLE Trial
    Moleculin Hits 45-Patient Enrollment Milestone in MIRACLE Trial

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260393/0/en/Moleculin-Hits-45-Subject-Enrollment-Milestone-Triggering-Final-Countdown-to-Mid-2026-MIRACLE-Trial-Data-Readout.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Moleculin Releases CEO Corner Segment On MIRACLE Study
    Moleculin Releases CEO Corner Segment On MIRACLE Study

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3253793/0/en/Moleculin-Releases-Next-CEO-Corner-Segment-Highlighting-MIRACLE-Study.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share
    Moleculin Confirms Annamycin's Safety On Heart In 90-Person Study
    Moleculin Confirms Annamycin's Safety On Heart In 90-Person Study

    13 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/13/3217831/0/en/Moleculin-Reports-Independent-Assessment-Confirms-No-Cardiotoxicity-of-Annamycin-in-90-Subjects.html

    GLOBENEWSWIRE
    13 Jan 2026
    Share Share
    Moleculin Accelerates 2026 Outlook with Global Pivotal Unblinding
    Moleculin Accelerates 2026 Outlook with Global Pivotal Unblinding

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216928/0/en/Moleculin-Accelerates-Outlook-Into-2026-With-First-Pivotal-Trial-Unblinding-on-Track-Global-Trial-Expansion-and-Multiple-Externally-IIT-Funded-Clinical-Programs.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Moleculin Completes Dosing 45 Patients in MIRACLE AML Trial
    Moleculin Completes Dosing 45 Patients in MIRACLE AML Trial

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202323/0/en/Moleculin-Announces-Completion-of-Treatment-for-the-45-Patients-in-Pivotal-MIRACLE-Phase-3-AML-Trial-on-Pace-for-Q1-2026.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    Moleculin Announces New Annamycin Collaboration in Brain Tumors
    Moleculin Announces New Annamycin Collaboration in Brain Tumors

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201521/0/en/Moleculin-Announces-New-Annamycin-Collaboration-in-Brain-Tumors.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.